Monoclonal antibodies and prostate-specific membrane antigen

Area of Science:

• Oncology
• Biomarker Discovery
• Molecular Imaging

Background:

• Prostate-specific membrane antigen (PSMA) is a transmembrane protein highly expressed in prostate tissue.
• PSMA exhibits increased binding affinity for malignant prostate cells, making it a valuable marker.
• Recent findings show PSMA expression in the neovasculature of various non-prostate tumors.

Purpose of the Study:

• To highlight the expanding role of PSMA as a diagnostic and therapeutic marker.
• To explore the potential of PSMA in non-prostate malignancies.
• To emphasize the significance of developing anti-PSMA monoclonal antibodies (mAbs).

Main Methods:

• Review of recent studies on PSMA expression in different cancer types.
• Analysis of PSMA's presence in tumor-associated neovasculature.
• Consideration of advancements in anti-PSMA antibody development.

Main Results:

• PSMA is highly expressed across all stages of prostate cancer.
• PSMA is also found in the endothelial cells of tumor neovasculature in colon, breast, bladder, pancreas, kidney cancers, and melanoma.
• Development of anti-PSMA mAbs is ongoing and improving.

Conclusions:

• PSMA is a crucial marker for prostate cancer, with expanding utility in other cancers.
• Targeting PSMA offers promising avenues for future cancer diagnostics and therapeutics.
• Further development of anti-PSMA antibodies will enhance its clinical applications across multiple malignancies.